Granite Point Capital Management, L.P. Sarepta Therapeutics, Inc. Transaction History

Granite Point Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 30, 2019	SELL	$72.81 - $156.91 $582,480 - $1.26 Million	-8,000 Closed	0 $0
Q2 2019 Jul 29, 2019	SELL	$112.21 - $151.95 $1.4 Million - $1.9 Million	-12,500 Reduced 60.98%	8,000 $1.22 Million
Q3 2018 Nov 13, 2018	SELL	$115.31 - $161.51 $832,538 - $1.17 Million	-7,220 Reduced 26.05%	20,500 $3.31 Million
Q2 2018 Aug 13, 2018	SELL	$71.74 - $153.69 $236,741 - $507,177	-3,300 Reduced 10.64%	27,720 $3.66 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $713,064 - $1.09 Million	-13,200 Reduced 29.85%	31,020 $2.3 Million

Q4 2017 Feb 08, 2018	SELL	$47.64 - $56.75 $109,572 - $130,525	-2,300 Reduced 4.94%	44,220 $2.46 Million
Q3 2017 Nov 14, 2017	SELL	$35.73 - $47.15 $596,691 - $787,405	-16,700 Reduced 26.42%	46,520 $2.11 Million
Q2 2017 Aug 10, 2017	BUY	N/A	63,220	63,220 $2.13 Million

479

79.3M

4.23M

1.21M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $12.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.